As global markets navigate a tumultuous landscape marked by escalating trade tensions and fluctuating consumer sentiment, the tech sector remains a focal point for investors seeking growth ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.